about
The effect of disease modifying therapies on brain atrophy in patients with relapsing-remitting multiple sclerosis: a systematic review and meta-analysisPlasma neurofilament heavy chain levels correlate to markers of late stage disease progression and treatment response in SOD1(G93A) mice that model ALSHow type I interferons work in multiple sclerosis and other diseases: some unexpected mechanisms.Increased neurofilament light chain blood levels in neurodegenerative neurological diseases.Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the futurePlasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study.Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis.Randomized study combining interferon and glatiramer acetate in multiple sclerosisCSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome.The impact of chemotherapy on cognitive outcomes in adults with primary brain tumors.Neurofilaments as biomarkers in multiple sclerosis.Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome.Fluid biomarker and electrophysiological outcome measures for progressive MS trials.The Validation Study of Neurofilament Heavy Chain and 8-hydroxy-2'-deoxyguanosine as Plasma Biomarkers of Clinical/Paraclinical Activity in First and Relapsing-Remitting Demyelination Acute Attacks.Brain atrophy after bone marrow transplantation for treatment of multiple sclerosis.Hyperacute detection of neurofilament heavy chain in serum following stroke: a transient sign.
P2860
Q26824991-9BAB425C-02AD-4224-9867-1BB445A6A516Q28481340-EDFCCADF-34A9-44AD-8C8D-212D56FCFD18Q33988240-9D44F025-6B4E-4F03-99B5-172D12F99269Q35000781-31A2C4EC-9F6D-4567-BB06-CA026BB374ACQ35078327-05EA08CE-AD53-4450-9BCF-B7254450B8A7Q35550715-8F1341D0-90B5-47C2-A4A9-C55A76AFDE8EQ35686186-EFC42506-F9EC-4C84-B562-0C7EA9BA8064Q36780801-4CA92BE5-020A-45D4-BD19-756136391E4FQ36840016-DAB86148-D472-4A37-BCED-3E55F6E693E2Q37986511-20733CA8-E61A-4079-9B7E-BAC094DE4B4CQ38001602-A920BD12-3C4D-4663-BDF5-7FE3132B6A44Q39035274-5DD8DF3B-EF0F-43F1-B2AE-AC21FEBF13A9Q47638443-96755AA4-BE1F-4529-A303-BBE5DE582397Q48681179-F0EF32BF-4D3A-4016-A965-B7797C8C381CQ48704224-9995E851-F96B-40DB-9481-E34839FCA07DQ48986769-9DFC8783-6477-429E-BEF0-90BE455DB17C
P2860
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Evidence for acute neurotoxicity after chemotherapy.
@en
Evidence for acute neurotoxicity after chemotherapy.
@nl
type
label
Evidence for acute neurotoxicity after chemotherapy.
@en
Evidence for acute neurotoxicity after chemotherapy.
@nl
prefLabel
Evidence for acute neurotoxicity after chemotherapy.
@en
Evidence for acute neurotoxicity after chemotherapy.
@nl
P2093
P2860
P50
P356
P1433
P1476
Evidence for acute neurotoxicity after chemotherapy.
@en
P2093
Axel Petzold
Jan Cornelissen
Jens Kuhle
Maria A Rocca
Massimo Filippi
Peter te Boekhorst
Rogier Hintzen
Tjeerd Mondria
P2860
P304
P356
10.1002/ANA.22169
P577
2010-12-01T00:00:00Z